NCT00268879View on ClinicalTrials.gov

Investigation of the Safety and Efficacy of Renzapride in Constipation Predominant Irritable Bowel Syndrome (IBS)

PHASE3CompletedINTERVENTIONAL
Enrollment

1,821

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

January 31, 2008

Study Completion Date

January 31, 2008

Conditions
Irritable Bowel Syndrome
Interventions
DRUG

Renzapride

Placebo Renzapride 4 mg QD Renzapride 2 mg BID

Trial Locations (1)

Unknown

Alizyme, Cambridge

Sponsors

Lead Sponsor

Alizyme
All Listed Sponsors
lead

Alizyme

INDUSTRY

NCT00268879 - Investigation of the Safety and Efficacy of Renzapride in Constipation Predominant Irritable Bowel Syndrome (IBS) | Biotech Hunter | Biotech Hunter